


BIM-23027

Cat. No.:	HY-P3958
CAS No.:	78981-49-4
Molecular Formula:	C ₄₃ H ₅₄ N ₈ O ₇
Molecular Weight:	794.94
Sequence Shortening:	Cyclo[[(NMe)Ala]-FWKTF]
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BIM-23027 is a selective agonist of sst ₂ receptor (EC ₅₀ =0.32 nM), with similar effect to somatostatin (SRIF), a cyclic tetradecapeptide. BIM-23027 stimulates dopamine release, which is mediated by a Glu-dependent mechanism ^{[1][2]} .
IC₅₀ & Target	<p>Caution: Product has not been fully validated for medical applications. For research use only.</p> <p>EC₅₀: 0.32 nM (sst₂)^[2] Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com</p>
In Vitro	<p>BIM-23027 (10, 50, and 100 nM; 90 min) significantly increases the level of dopamine^[1]. BIM-23027 (50 nM; 15 min prior to SRIF (100 nM)) significantly attenuates the actions of the naturally-occurring peptide^[1].</p> <p>BIM-23027 (30 nM; 30 min) carbachol-stimulated increases in basal SCC by 60-70%, with an EC₅₀ value of 0.29 nM^[2]. BIM-23027 interacts with a sub-population of [125I]Tyr11-SRIF binding sites in rat colonic mucosal membranes^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Hathway GJ, et al. Evidence that somatostatin sst₂ receptors mediate striatal dopamine release. Br J Pharmacol. 1999 Nov;128(6):1346-52.
- [2]. McKeen ES, et al. Somatostatin receptors mediating inhibition of basal and stimulated electrogenic ion transport in rat isolated distal colonic mucosa. Naunyn Schmiedebergs Arch Pharmacol. 1995 Oct;352(4):402-11.